SEC filings and other documents

VK2735 delivers up to 14.7% mean weight loss in Phase 2, with Phase 3 trials fully enrolled.

Phase III obesity trials progress, oral program set for Q4, cash runway extends into 2028.

VK2735 delivers up to 15% weight loss in late-stage trials with strong safety and cash reserves.

VK2735 achieved up to 14.7% mean weight loss in Phase 2, with Phase 3 trials ongoing.

Obesity and oral phase III trials advance, with robust funding and new amylin program underway.

VK2735 phase III trials fully enrolled; R&D spend up, cash supports operations into 2028.

VK2735 achieved up to 14.7% weight loss in Phase 2 obesity trials with strong tolerability.

Rapid phase III progress and differentiated obesity therapies set up major 2026 data milestones.

VK2735 achieved up to 14.7% mean weight loss in Phase 2, with strong durability and safety.

VK2735 shows robust, durable weight loss in phase II; phase III trials and maintenance studies advance.

Advanced VK2735 obesity programs to Phase III with strong results; cash supports key milestones.

VK2735 achieved up to 15% weight loss in trials, with strong durability and a robust cash position.

Lead obesity candidate VK2735 shows robust efficacy and durability in phase II, with phase III underway.

Strong Phase 2 data and accelerated Phase 3 enrollment drive clinical and financial momentum.

Lead obesity drug VK2735 achieved up to 14.7% weight loss and is advancing in Phase 3 trials.

Lead obesity drug shows strong efficacy and tolerability, with lean strategy and ample funding.

Phase III obesity trials show strong progress, with robust efficacy and secure manufacturing capacity.

Oral VK2735 achieved significant weight loss and favorable safety in phase II, supporting further development.

Phase III obesity trials launched, cash strong, and key data readouts expected in H2 2025.